SeaStar Medical Holding Corporation reported financial results for the second quarter ended June 30, 2026. Net revenue increased 82% to $0.6 million from $0.3 million in the prior year period, driven by QUELIMMUNE product sales. The company incurred a net loss of $3.7 million, or $0.91 per share, compared to a $2.0 million loss in the same quarter last year. Cash reserves declined to $7.0 million from $12.0 million at year-end 2025. Research and development expenses rose to $2.5 million due to clinical trial costs, while general and administrative expenses increased to $1.8 million. The company added three new pediatric hospital customers for its QUELIMMUNE therapy and advanced enrollment in the NEUTRALIZE-AKI pivotal trial to 223 of 339 patients. CMS issued dedicated ICD-10-PCS codes for SCD therapy, effective October 1, 2026. SeaStar Medical is a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure.